Pacira BioSciences has reported preliminary fourth-quarter net product sales for its flagship product, Exparel, that surpassed analyst expectations, driving investor enthusiasm. The company announced Exparel sales of $147.7 million for the quarter, reflecting a robust performance attributed to increased volume and favorable pricing dynamics. This positive sales momentum is part of Pacira's broader strategic
Pacira BioSciences, Inc. (PCRX) shares are seeing an uptick in after-hours trading following the announcement of positive 104-week safety and efficacy data for PCRX-201, a treatment for moderate to severe osteoarthritis of the knee. This long-term data supports the potential of PCRX-201 as a viable option for patients suffering from this condition, which could enhance the company's market position in the os
Pacira BioSciences, Inc. (PCRX) shares are experiencing an uptick today, potentially driven by technical trading signals. According to a report released on December 16, 2024, at 9:48 am ET, technical analysis suggests a buy signal for PCRX if it breaks above the resistance level of $19.79, with an upside target of $21.1. This technical setup may have encouraged traders to enter long positions, contributing